2016_Head & Neck COURSE BOOK

• Median survival of patients is 10-12 months (? Immunotherapy)

• First-line: Cisplatin /5-FU/cetuximab: standard of care • Second-line: nivolumab

• Options: Platin/paclitaxel, taxanes, methotrexate